Ignite Creation Date:
2025-12-25 @ 12:26 AM
Ignite Modification Date:
2025-12-29 @ 11:00 AM
Study NCT ID:
NCT05740358
Status:
RECRUITING
Last Update Posted:
2025-05-22
First Post:
2023-02-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Liver Cirrhosis Network Cohort Study
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D005355', 'term': 'Fibrosis'}, {'id': 'D008103', 'term': 'Liver Cirrhosis'}, {'id': 'D008104', 'term': 'Liver Cirrhosis, Alcoholic'}, {'id': 'D008105', 'term': 'Liver Cirrhosis, Biliary'}, {'id': 'C562577', 'term': 'Cirrhosis, Cryptogenic'}, {'id': 'D019693', 'term': 'Hepatitis, Autoimmune'}, {'id': 'D065626', 'term': 'Non-alcoholic Fatty Liver Disease'}], 'ancestors': [{'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D008107', 'term': 'Liver Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D008108', 'term': 'Liver Diseases, Alcoholic'}, {'id': 'D020751', 'term': 'Alcohol-Induced Disorders'}, {'id': 'D019973', 'term': 'Alcohol-Related Disorders'}, {'id': 'D019966', 'term': 'Substance-Related Disorders'}, {'id': 'D064419', 'term': 'Chemically-Induced Disorders'}, {'id': 'D002780', 'term': 'Cholestasis, Intrahepatic'}, {'id': 'D002779', 'term': 'Cholestasis'}, {'id': 'D001649', 'term': 'Bile Duct Diseases'}, {'id': 'D001660', 'term': 'Biliary Tract Diseases'}, {'id': 'D006521', 'term': 'Hepatitis, Chronic'}, {'id': 'D006505', 'term': 'Hepatitis'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D005234', 'term': 'Fatty Liver'}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Blood, urine, saliva, stool (optional)'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 1200}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2022-11-18', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-05', 'completionDateStruct': {'date': '2028-07-25', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-05-19', 'studyFirstSubmitDate': '2023-02-08', 'studyFirstSubmitQcDate': '2023-02-21', 'lastUpdatePostDateStruct': {'date': '2025-05-22', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2023-02-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2028-07-25', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Time-to-decompensation', 'timeFrame': '3 years', 'description': 'Time-to-decompensation, defined as any of the following events:\n\n* Ascites: definite as determined by adjudication\n* Hepatic Encephalopathy (HE): definite or highly likely as determined by adjudication\n* Portal hypertensive upper gastrointestinal (GI) bleeding: definite as determined by adjudication'}], 'secondaryOutcomes': [{'measure': 'Number of decompensations', 'timeFrame': '3 years', 'description': 'Number of decompensations (treated as a count variable in analyses)'}, {'measure': 'All-cause mortality', 'timeFrame': '3 years', 'description': 'All-cause mortality (treated as time-to-event in analyses)'}, {'measure': 'Adjudicated liver-related mortality', 'timeFrame': '3 years', 'description': 'Adjudicated liver-related mortality (treated as time-to-event in analyses)'}, {'measure': 'All-cause hospitalizations', 'timeFrame': '3 years', 'description': 'All-cause hospitalizations (treated as a count variable in analyses)'}, {'measure': 'Number of liver-related hospitalizations', 'timeFrame': '3 years', 'description': 'Liver-related hospitalizations (treated as a count variable in analyses)'}, {'measure': 'Time to liver transplantation', 'timeFrame': '3 years', 'description': 'Liver transplantation (treated as time-to-event in analyses)'}, {'measure': 'Time to development of hepatocellular carcinoma (HCC)', 'timeFrame': '3 years', 'description': 'Development of HCC (treated as time-to-event in analyses)'}, {'measure': 'Time to development of portal and/or mesenteric vein thrombosis', 'timeFrame': '3 years', 'description': 'Development of portal and/or mesenteric vein thrombosis (treated as time-to-event in analyses)'}, {'measure': 'Change in liver stiffness as measured by vibration-controlled transient elastography (VCTE)', 'timeFrame': '3 years', 'description': 'Liver stiffness as measured by VCTE (treated as continuous measure in analyses)'}, {'measure': 'Degree of fibrosis as measured by fibrosis-4 index (FIB-4)', 'timeFrame': '3 years', 'description': 'Degree of fibrosis as measured by FIB-4 (treated as continuous measure in analyses)'}, {'measure': 'Overall physical health and overall mental health as measured by Patient Reported Outcomes Measurement Information System (PROMIS-29+2 profile v2.1)', 'timeFrame': '3 years', 'description': 'Overall physical health and overall mental health as measured by Patient Reported Outcomes Measurement Information System (PROMIS-29+2 profile v2.1) relevant "T-scores," a continuous measure. T-scores are normalized to the population and are centered at 50 with anticipated standard deviation of 10. A higher score means better "health."'}, {'measure': 'Change in cognitive function as measured by Stroop Test', 'timeFrame': '3 years', 'description': 'Change in cognitive function as measured by Stroop Test (treated as continuous measure in analyses). Measured as time to complete the test. A higher score means longer time to complete, which means more impaired function. Minimum score is 0, and there is no maximum score.'}, {'measure': 'Change in frailty as measured by the Liver Frailty Index', 'timeFrame': '3 years', 'description': 'Change in frailty as measured by the Liver Frailty Index (treated as continuous measure in analyses). A higher score means the participant is more frail. The score is based on grip strength, number of chair stands per second, and balance time. https://liverfrailtyindex.ucsf.edu/ Maximum score of 6, and there is no minimum score.'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Cirrhosis', 'Liver', 'Nonalcoholic Fatty Liver Disease', 'NASH', 'Nonalcoholic steatohepatitis'], 'conditions': ['Cirrhosis', 'Cirrhosis, Liver', 'Cirrhosis Early', 'Cirrhosis Due to Hepatitis B', 'Cirrhosis Advanced', 'Cirrhosis Infectious', 'Cirrhosis Alcoholic', 'Cirrhosis, Biliary', 'Cirrhosis Cryptogenic', 'Cirrhosis Due to Hepatitis C', 'Cirrhosis Due to Primary Sclerosing Cholangitis', 'Autoimmune Hepatitis']}, 'referencesModule': {'references': [{'pmid': '39018024', 'type': 'DERIVED', 'citation': 'Tapper EB, Goldberg D, Parikh ND, Terrault NA, Welch N, Sharpton S, Hameed B, Khalili M, Stolz A, Verna EC, Brown RS Jr, Sanyal AJ, VanWagner L, Ladner DP, Moylan CA, Diehl AM, Jones PD, Loomba R, Dasarathy S, Simonetto DA, Shah VH, Bajaj JS; LCN Study Group. The Liver Cirrhosis Network Cohort Study: Cirrhosis Definition, Study Population, and Endpoints. Am J Gastroenterol. 2025 Mar 1;120(3):570-575. doi: 10.14309/ajg.0000000000002953. Epub 2024 Jul 17.'}], 'seeAlsoLinks': [{'url': 'https://www.lcnstudy.org', 'label': 'Information about the study'}]}, 'descriptionModule': {'briefSummary': 'Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months (180 days), with opportunities to complete specific visit components via telehealth or remotely. Visits will include collection of questionnaire data and the in-person visits will include questionnaires, physical exams, imaging, and sample collection.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'The study will include participants with cirrhosis of the liver.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Age ≥ 18 years\n* Willing to provide samples at baseline\n* Cirrhosis\n\nWhere Cirrhosis is defined as:\n\n1. At least one liver biopsy within 5 years prior to consent showing either: a) Metavir stage 4 fibrosis; Ishak Stage 5-6 fibrosis OR\n2. At least 2 of the following:\n\n1\\. Evidence on imaging: Nodular liver with either splenomegaly or recanalized umbilical vein within the past year 2. Liver stiffness: VCTE within one year prior to consent or during Screening ≥12.5 kPa or MRE within one year prior to consent or during Screening ≥5 kPa 3. Evidence of varices demonstrated on imaging or endoscopy within 3 years prior to consent or during Screening 4. Either: FIB-4\\>2.67 or platelets \\<150/mL within 6 months prior to consent or during Screening 5. \\>5 years METAVIR stage 4 fibrosis or Ishak stage 5-6\n\nExclusion Criteria:\n\n* Known and documented prior or current hepatocellular carcinoma (HCC) or cholangiocarcinoma\n* Known transjugular intrahepatic portosystemic shunt (TIPS), balloon retrograde transvenous obliteration (BRTO) or porto-systemic shunt surgery regardless of time of occurrence\n* Known prior solid organ transplant or bone marrow transplant\n* Current participation in active medication treatment trials at the time of consent for LCN Cohort Study\n* Prisoners or individuals with more than 180 days incarceration pending due to difficulty with visits\n* Bariatric surgery in the last 180 days prior to consent\n* Known history of fontan procedure-associated liver disease (FALD)\n* Known current medical or psychiatric conditions which, in the opinion of the investigator, would make the participant unsuitable for the study or interfere with or prevent follow-up per protocol\n* Current liver-unrelated end-stage organ failures (Dialysis, stage 3-4 congestive heart failure (CHF), current chronic obstructive pulmonary disease (COPD) on home oxygen, current known active malignancy besides non-melanomatous skin cancer or carcinoma in situ)\n* Documented history of acute alcohol-associated hepatitis (according to NIAAA criteria as described in the MOP) in the 180 days prior to consent\n* Documented current or continued signs and symptoms of acute Wilson disease (acute liver failure, acute neurological deficits, hemolysis)\n* In patients with primary sclerosing cholangitis (PSC): Current active cholangitis with 90 days prior to consent\n* Documented cardiac cirrhosis\n* Known recent (within the last 365 days) or present hepatic decompensation with ascites/hydrothorax (including trace ascites discovered at screening not requiring intervention), hepatic encephalopathy or variceal bleeding. If a patient has had a history of decompensation, they must have been off any medications to treat decompensation for at least 365 days. Refer to the MOP for clarifying details on evaluating eligibility for patients with a history of prior decompensation.\n* Known or documented habitual non-adherence to previous research studies or medical procedures or unwillingness to adhere to protocol (e.g., unwilling to obtain consent or samples)\n* Current model for end-stage liver disease (MELD-Na) cut off ≥ 15\\*\n* Current Child-Turcotte-Pugh (CTP) B or C\\*\n* Current known Hepatitis C Virus (HCV) without sustained virologic response (SVR)\n* Current known quantifiable Hepatitis B Virus (HBV) viral DNA on therapy with ongoing adherence on suppressive therapy\\*\n* In patients with autoimmune hepatitis: serum aspartate aminotransferase (AST) \\> 2X upper limit of normal (ULN) within 90 days prior to consent or during Screening\\*\n* In patients living with HIV: CD4+ T cell count less than 100 cells/mm3 within 90 days prior to consent or during Screening\\*\n\n * Indicates an exclusion criterion that may depend on laboratory results and other clinical assessments to be ordered during Screening after confirming the participant is otherwise eligible. If the test was performed as standard-of-care in the 90 days prior to consent, it does not need to be re-done for eligibility.'}, 'identificationModule': {'nctId': 'NCT05740358', 'acronym': 'LCN-C', 'briefTitle': 'Liver Cirrhosis Network Cohort Study', 'organization': {'class': 'OTHER', 'fullName': 'Northwestern University'}, 'officialTitle': 'Liver Cirrhosis Network Cohort Study', 'orgStudyIdInfo': {'id': 'LCN Cohort Study'}, 'secondaryIdInfos': [{'id': '1U24DK130164-01', 'link': 'https://reporter.nih.gov/quickSearch/1U24DK130164-01', 'type': 'NIH'}, {'id': 'Pro00064389', 'type': 'OTHER', 'domain': 'Advarra, Inc.'}, {'id': '5U01DK130177-02', 'link': 'https://reporter.nih.gov/quickSearch/5U01DK130177-02', 'type': 'NIH'}, {'id': '5U01DK130197-02', 'link': 'https://reporter.nih.gov/quickSearch/5U01DK130197-02', 'type': 'NIH'}, {'id': '5U01DK130185-02', 'link': 'https://reporter.nih.gov/quickSearch/5U01DK130185-02', 'type': 'NIH'}, {'id': '5U01DK130180-02', 'link': 'https://reporter.nih.gov/quickSearch/5U01DK130180-02', 'type': 'NIH'}, {'id': '5U01DK130221-02', 'link': 'https://reporter.nih.gov/quickSearch/5U01DK130221-02', 'type': 'NIH'}, {'id': '5U01DK130134-02', 'link': 'https://reporter.nih.gov/quickSearch/5U01DK130134-02', 'type': 'NIH'}, {'id': '5U01DK130168-02', 'link': 'https://reporter.nih.gov/quickSearch/5U01DK130168-02', 'type': 'NIH'}, {'id': '5U01DK130190-02', 'link': 'https://reporter.nih.gov/quickSearch/5U01DK130190-02', 'type': 'NIH'}, {'id': '5U01DK130113-02', 'link': 'https://reporter.nih.gov/quickSearch/5U01DK130113-02', 'type': 'NIH'}, {'id': '5U01DK130181-02', 'link': 'https://reporter.nih.gov/quickSearch/5U01DK130181-02', 'type': 'NIH'}, {'id': '5U24DK130164-02', 'link': 'https://reporter.nih.gov/quickSearch/5U24DK130164-02', 'type': 'NIH'}]}, 'contactsLocationsModule': {'locations': [{'zip': '92035', 'city': 'La Jolla', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Rohit Loomba', 'role': 'CONTACT', 'email': 'roloomba@health.ucsd.edu'}], 'facility': 'University of California San Diego NAFLD Research Center', 'geoPoint': {'lat': 32.84727, 'lon': -117.2742}}, {'zip': '90033', 'city': 'Los Angeles', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Norah Terrault', 'role': 'CONTACT', 'email': 'norah.terrault@med.usc.edu'}], 'facility': 'Keck Medical Center of USC', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '90033', 'city': 'Los Angeles', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Norah Terrault', 'role': 'CONTACT', 'email': 'norah.terrault@med.usc.edu'}], 'facility': 'LAC + USC Medical Center', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '94110', 'city': 'San Francisco', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Mandana Khalili', 'role': 'CONTACT', 'email': 'Mandana.Khalili@ucsf.edu'}], 'facility': 'UCSF/Zuckerberg San Francisco General Hospital and Trauma Center', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'zip': '94143', 'city': 'San Francisco', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Bilal Hameed', 'role': 'CONTACT', 'email': 'bilal.hameed@ucsf.edu'}], 'facility': 'UCSF Medical Center', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'zip': '33122', 'city': 'Miami', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'David Goldberg', 'role': 'CONTACT', 'email': 'dsgoldberg@med.miami.edu'}], 'facility': 'University of Miami Health System', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '48109', 'city': 'Ann Arbor', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Elliot Tapper', 'role': 'CONTACT', 'email': 'etapper@med.umich.edu'}], 'facility': 'University of Michigan', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}, {'zip': '55901', 'city': 'Rochester', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Vijay Shah', 'role': 'CONTACT', 'email': 'Shah.Vijay@mayo.edu'}], 'facility': 'Mayo Clinic', 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}, {'zip': '10021', 'city': 'New York', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Robert Brown', 'role': 'CONTACT', 'email': 'rsb2005@med.cornell.edu'}], 'facility': 'New York Presbyterian/Weill Cornell', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10031', 'city': 'New York', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Elizabeth Verna', 'role': 'CONTACT', 'email': 'ev77@cumc.columbia.edu'}], 'facility': 'Columbia University Iriving School of Medicine', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '27710', 'city': 'Durham', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Cynthia Moylan', 'role': 'CONTACT', 'email': 'cynthia.moylan@duke.edu'}], 'facility': 'Duke Liver Center', 'geoPoint': {'lat': 35.99403, 'lon': -78.89862}}, {'zip': '44192', 'city': 'Cleveland', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Srinivasan Dasarathy', 'role': 'CONTACT', 'email': 'DASARAS@ccf.org'}], 'facility': 'Cleveland Clinic', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '23249', 'city': 'Richmond', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Jasmohan Bajaj', 'role': 'CONTACT', 'email': 'jasmohan.bajaj@vcuhealth.org', 'phone': '804-828-4060'}], 'facility': 'Central Virginia Veterans Healthcare System', 'geoPoint': {'lat': 37.55376, 'lon': -77.46026}}, {'zip': '23298', 'city': 'Richmond', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Arun Sanyal', 'role': 'CONTACT', 'email': 'arun.sanyal@vcuhealth.org'}], 'facility': 'Virginia Commonwealth University', 'geoPoint': {'lat': 37.55376, 'lon': -77.46026}}], 'centralContacts': [{'name': 'Crystal K Santillanes, MS', 'role': 'CONTACT', 'email': 'lcn@northwestern.edu', 'phone': '312-503-5536'}], 'overallOfficials': [{'name': 'Jody Ciolino', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Northwestern University'}]}, 'ipdSharingStatementModule': {'infoTypes': ['STUDY_PROTOCOL'], 'ipdSharing': 'YES', 'description': 'Dataset with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Repository.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Northwestern University', 'class': 'OTHER'}, 'collaborators': [{'name': 'The Cleveland Clinic', 'class': 'OTHER'}, {'name': 'Columbia University', 'class': 'OTHER'}, {'name': 'Weill Medical College of Cornell University', 'class': 'OTHER'}, {'name': 'Duke University', 'class': 'OTHER'}, {'name': 'Mayo Clinic', 'class': 'OTHER'}, {'name': 'University of Miami', 'class': 'OTHER'}, {'name': 'University of Michigan', 'class': 'OTHER'}, {'name': 'University of California, San Diego', 'class': 'OTHER'}, {'name': 'University of California, San Francisco', 'class': 'OTHER'}, {'name': 'LAC+USC Medical Center', 'class': 'OTHER'}, {'name': 'Virginia Commonwealth University', 'class': 'OTHER'}, {'name': 'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)', 'class': 'NIH'}, {'name': 'National Institute on Alcohol Abuse and Alcoholism (NIAAA)', 'class': 'NIH'}, {'name': 'National Cancer Institute (NCI)', 'class': 'NIH'}, {'name': 'University of Southern California', 'class': 'OTHER'}, {'name': 'Central Virginia Veterans Healthcare System', 'class': 'UNKNOWN'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Associate Professor', 'investigatorFullName': 'Jody D. Ciolino', 'investigatorAffiliation': 'Northwestern University'}}}}